Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Real world data for len/dex in second-line myeloma: what does this tell us?

Evangelos Terpos • 10 Oct 2018
ESH MM 2018
Multiple Myeloma Dexamethasone Lenalidomide

Real world data can shed new light upon the results of similar treatments in trials, as the study discussed here by Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, did. Dr Terpos discusses what the real world data for lenalidomide plus dexamethasone in the second-line setting for multiple myeloma (MM) has revealed. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Evangelos Terpos

2:39
Antibody response to COVID-19 vaccine in patients with multiple myeloma and WM
Evangelos Terpos • 10 Dec 2022
2:02
Ocular AEs observed in patients treated with belantamab mafodotin, lenalidomide & dexamethasone
Evangelos Terpos • 10 Dec 2022
1:14
BelaRd: belantamab mafodotin with lenalidomide and dexamethasone in patients with NDMM
Evangelos Terpos • 10 Dec 2022
3:03
The prognostic impact of circulating plasma cells in patients with multiple myeloma
Evangelos Terpos • 10 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals